NEW YORK (GenomeWeb) – Israeli epigenetics-based diagnostics firm Nucleix announced on Monday that it has raised more than $5 million in private financing.

The company's lead product is the urine-based Bladder EpiCheck for detecting bladder cancer. The funding will go toward clinical trials for the test, as well as efforts to gain European CE marking and US Food and Drug Administration regulatory approval, Tel Aviv, Israel-based Nucleix said. Funds will also be used to develop diagnostic tests for other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.